Wharton’s Jelly MSCs: Potential Weapon to Sharpen for Our Battle against DM

Publication date: Available online 5 February 2020Source: Trends in Endocrinology & MetabolismAuthor(s): Dina H. Kassem, Mohamed M. KamalDiabetes mellitus (DM) is a devastating metabolic disease. Stem cell therapy provides great hope to all diabetic patients. Umbilical cord (UC) Wharton’s jelly mesenchymal stem cells (WJ-MSCs) specifically provides a potential cell therapy for DM. In this article, we discuss major advantages of WJ-MSCs and challenges facing their clinical utility in DM.
Source: Trends in Endocrinology and Metabolism - Category: Endocrinology Source Type: research